Takuichiro Hide

Takuichiro Hide

Auto-generated profile, based on publicly available information

Takuichiro Hide

Department of Neurosurgery, Faculty of Life Sciences Research, Kumamoto University Graduate School, 1-1-1 Honjo, Chuo-ku, Kumamoto, 860-8556, Japan

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in Surgical Neurology International
Verified
Journal Article
Open access
PDF file
SYShigetoshi Yano
Shigetoshi Yano
THTakuichiro Hide
Takuichiro Hide
NSNaoki Shinojima
Naoki Shinojima
YHYu Hasegawa
Yu Hasegawa
TKTakayuki Kawano
Takayuki Kawano
JKJun-Ichi Kuratsu
Jun-Ichi Kuratsu
Background: Endoscopic surgery is suitable for the transsphenoidal approach; it is minimally invasive and provides a well-lit operative field. The endoscopic skull base approach through the large opening of the sphenoid sinus through both nostrils has extended the surgical indication for various skull base lesions. In this study, we describe the efficacy and complications associated with the endoscopic skull base approach for extra- or intradural parasellar lesions based on our experiences. Methods: Seventy-four cases were treated by an endoscopic skull base approach. The indications for these procedures included 55 anterior extended approaches, 10 clival approaches, and 9 cavernous approaches. The operations were performed through both the nostrils using a rigid endoscope. After tumor removal, the skull base was reconstructed by a multilayered method using a polyglactin acid (PGA) sheet. Results: Gross total resection was achieved in 82% of pituitary adenomas, 68.8% of meningiomas, and 60% of craniopharyngiomas in anterior extended approach and in 83.3% of chordomas in clival approach, but only in 50% of the tumors in cavernous approach. Tumor consistency, adhesion, and/or extension were significant limitations. Visual function improvements were achieved in 37 of 41 (90.2%) cases. Cerebrospinal fluid (CSF) leakage (9.5%), infections (5.4%), neural injuries (4.1%), and vascular injuries (2.7%) were the major complications. Conclusions: Our experiences show that the endoscopic skull base approach is a safe and effective procedure for various parasellar lesions. Selection of patients who are unlikely to develop complications seems to be an important factor for procedure efficacy and good outcome.

1 January 2013 in Surgical Neurology International
Verified
Journal Article
Open access
SYShigetoshi Yano
Shigetoshi Yano
TYTakahiro Yamamoto
Takahiro Yamamoto
THTakuichiro Hide
Takuichiro Hide
JKJun-Ichi Kuratsu
Jun-Ichi Kuratsu
Ecchordosis physaliphora (EP) is a benign notochordal remnant that is usually asymptomatic; symptomatic cases are extremely rare. Most of the reported symptomatic cases were managed by resection via craniotomy. We report a case of a 20-year-old male presenting with abducens nerve palsy. Magnetic resonance imaging performed on admission demonstrated a mass in the retroclival prepontine location. The patient was treated successfully by endoscopic endonasal trans-sphenoidal surgery (ETSS), his postoperative course was uneventful, and the abducens nerve palsy disappeared. ETSS has advantages not only for treatment but also for differentiation between EP and intradural chordoma. This is the first case of symptomatic EP successfully treated solely by ETSS.

6 November 2008 in Brain Tumor Pathology
Verified
Journal Article
Closed access
PDF file
THTakuichiro Hide
Takuichiro Hide
TTTatsuya Takezaki
Tatsuya Takezaki
HNHideo Nakamura
Hideo Nakamura
JKJunichi Kuratsu
Junichi Kuratsu
TKToru Kondo
Toru Kondo

1 January 2013 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
YTYoshinobu Takahashi
Yoshinobu Takahashi
HNHideo Nakamura
Hideo Nakamura
KMKeishi Makino
Keishi Makino
THTakuichiro Hide
Takuichiro Hide
DMDaisuke Muta
Daisuke Muta
JKJun-Ichi Kuratsu
Jun-Ichi Kuratsu
To determine the prognostic value of isocitrate dehydrogenase 1 (IDH1) mutation, O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation, and 1p/19q co-deletion in Japanese patients with malignant gliomas. We studied 267 malignant gliomas, which included 171 glioblastomas (GBMs), 40 anaplastic astrocytomas (AAs), 30 anaplastic oligodendrogliomas (AOs), and 26 anaplastic oligoastrocytomas (AOAs). These malignant gliomas were divided into 2 groups (Group 1: GBM + AA, Group 2: AO + AOA) according to the presence of the oligodendroglioma component. We examined IDH1 mutation and MGMT promoter methylation in each group by direct sequencing and methylation-specific PCR, respectively. We further examined 1p/19q co-deletion in Group 2 by fluorescence in situ hybridization. Survival between groups was compared by Kaplan-Meier analysis. In Group 1, patients with IDH1 mutations exhibited a significantly longer survival time than patients with wild-type IDH1. However, no significant difference was observed in Group 2, although patients with IDH1 mutations tended to show prolonged survival. For both Group 1 and Group 2, patients with MGMT methylation survived longer than those without this methylation. Further, patients with 1p/19q co-deletion showed significantly better outcome in Group 2. Our study confirms the utility of IDH1 mutations and MGMT methylation in predicting the prognosis of Group 1 patients (GBM + AA) and demonstrated that IDH1 mutations may serve as a more reliable prognostic factor for such patients. We also showed that MGMT methylation and 1p/19q co-deletion rather than IDH1 mutations were prognostic factors for Group 2 patients (AOA + AO). Our study suggests that patients survive longer if they have IDH1 mutations and undergo total resection. Further, irrespective of MGMT promoter methylation status, the prognosis of glioma patients can be improved if total resection is performed. Moreover, our study includes the largest number of Japanese patients with malignant gliomas that has been analyzed for these three markers. We believe that our findings will increase the awareness of oncologists in Japan of the value of these markers for predicting prognosis and designing appropriate therapeutic strategies for treating this highly fatal disease.

19 April 2014 in Cancer Science
Verified
Journal Article
Open access
PDF file
SAShigeo Anai
Shigeo Anai
THTakuichiro Hide
Takuichiro Hide
TTTatsuya Takezaki
Tatsuya Takezaki
JKJun‐Ichiro Kuroda
Jun‐Ichiro Kuroda
NSNaoki Shinojima
Naoki Shinojima
JKJun‐Ichi Kuratsu
Jun‐Ichi Kuratsu
Temozolomide (TMZ), used to treat glioblastoma and malignant glioma, induces autophagy, apoptosis and senescence in cancer cells. We investigated fibrin glue (FG) as a drug delivery system for the local administration of high‐concentration TMZ aimed at preventing glioma recurrence. Our high‐power liquid chromatography studies indicated that FG containing TMZ (TMZ‐FG) manifested a sustained drug release potential. We prepared a subcutaneous tumor model by injecting groups of mice with three malignant glioma cell lines and examined the antitumor effect of TMZ‐FG. We estimated the tumor volume and performed immunostaining and immunoblotting using antibodies to Ki‐67, cleaved caspase 3, LC3 and p16. When FG sheets containing TMZ (TMZ‐FGS) were inserted beneath the tumors, their growth was significantly suppressed. In mice treated with peroral TMZ plus TMZ‐FGS the tumors tended to be smaller than in mice whose tumors were treated with TMZ‐FGS or peroral TMZ alone. The TMZ‐FGS induced autophagy, apoptosis and senescence in subcutaneous glioma tumor cells. To assess the safety of TMZ‐FG for normal brain, we placed it directly on the brain of living mice and stained tissue sections obtained in the acute and chronic phase immunohistochemically. In both phases, TMZ‐FG failed to severely damage normal brain tissue. TMZ‐FG may represent a safe new drug delivery system with sustained drug release potential to treat malignant glioma.

1 January 2013 in Neurologia medico-chirurgica
Verified
Journal Article
Open access
THTakuichiro Hide
Takuichiro Hide
KMKeishi Makino
Keishi Makino
HNHideo Nakamura
Hideo Nakamura
SYShigetoshi Yano
Shigetoshi Yano
SAShigeo Anai
Shigeo Anai
JKJun-Ichi Kuratsu
Jun-Ichi Kuratsu
Glioblastoma multiforme (GBM) harbors are not only rapidly dividing cells but also small populations of slowly dividing and dormant cells with tumorigenesity, self-renewal, and multi-lineage differentiation capabilities. Known as glioblastoma stem cells (GSCs), they are resistant to conventional chemo- and radiotherapy and may be a causative factor in recurrence. The treatment outcome in patients with GBM remains unsatisfactory and their mean survival time has not improved sufficiently. We studied clinical evidence and basic research findings to assess the possibility of new treatment strategies that target GSCs and their specific microenvironments (GBM niches) and raise the possibility of adding new treatments to eradicate GSCs and GBM niches.